Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan

Keishi Kido, Kayo Ibaragi, Mitsuyoshi Tanishima, Yosuke Muramoto, Shun Nakayama, Kohei Ata, Kenshi Hayashida, Hideki Nakamura, Yasuhiko Shinmura, Yoshiaki Oda, Masafumi Endo, Kengo Sonoda, Yuji Sasagawa, Yasuhiro Iwama, Kohji Ueda, Takayuki Matsumoto
doi: https://doi.org/10.1101/2022.10.27.22281603

Article Information

doi 
https://doi.org/10.1101/2022.10.27.22281603
History 
  • November 2, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Keishi Kido1,*,
  2. Kayo Ibaragi1,
  3. Mitsuyoshi Tanishima1,
  4. Yosuke Muramoto1,
  5. Shun Nakayama1,
  6. Kohei Ata1,
  7. Kenshi Hayashida1,
  8. Hideki Nakamura1,
  9. Yasuhiko Shinmura1,
  10. Yoshiaki Oda1,
  11. Masafumi Endo1,
  12. Kengo Sonoda1,
  13. Yuji Sasagawa2,
  14. Yasuhiro Iwama2,
  15. Kohji Ueda3 and
  16. Takayuki Matsumoto1
  1. 1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
  2. 2Meiji Seika Pharma Co., Ltd., Tokyo, Japan
  3. 3Professor emeritus, Kyushu University, Fukuoka, Japan
  1. ↵*CORRESPONDENCE
    Keishi Kido, KM Biologics Co., Ltd (KM Biologics), 869-1298 Kumamoto, Japan. Email: kido{at}kmbiologics.com
Back to top
Posted November 02, 2022.
Download PDF
Data/Code
Email
Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan
Keishi Kido, Kayo Ibaragi, Mitsuyoshi Tanishima, Yosuke Muramoto, Shun Nakayama, Kohei Ata, Kenshi Hayashida, Hideki Nakamura, Yasuhiko Shinmura, Yoshiaki Oda, Masafumi Endo, Kengo Sonoda, Yuji Sasagawa, Yasuhiro Iwama, Kohji Ueda, Takayuki Matsumoto
medRxiv 2022.10.27.22281603; doi: https://doi.org/10.1101/2022.10.27.22281603
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area